In summary, these results reveal that decreased TFEB expression maybe a key mechanism of mitochondrial dysfunction in cisplatin-induced AKI, and that upregulation of TFEB has the potential to act as a therapeutic target to alleviate mitochondrial dysfunction and cisplatin-induced TEC injury. This evidence concerns the gene TFEB and acute kidney injury.